Heliyon, Journal Year: 2024, Volume and Issue: 10(20), P. e38710 - e38710
Published: Oct. 1, 2024
Language: Английский
Clinical and Translational Medicine, Journal Year: 2024, Volume and Issue: 14(5)
Published: April 29, 2024
The current standard of care for locally advanced gastric cancer (GC) involves neoadjuvant chemotherapy followed by radical surgery. Recently, treatment this condition has involved the exploration immunotherapy plus as a potential approach. However, efficacy remains uncertain.
Language: Английский
Citations
9
Journal of Clinical Oncology, Journal Year: 2024, Volume and Issue: unknown
Published: Oct. 9, 2024
This multicenter, randomized phase III trial evaluated the efficacy and safety of perioperative camrelizumab (an anti-PD-1 antibody) plus low-dose rivoceranib (a VEGFR-2 inhibitor) S-1 oxaliplatin (SOX) (SOXRC), high-dose SOX (SOXR), alone for locally advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
Language: Английский
Citations
7
Journal of Translational Medicine, Journal Year: 2025, Volume and Issue: 23(1)
Published: March 24, 2025
Neoadjuvant immunotherapy has been shown to improve survival in patients with gastric cancer. This study sought develop and validate a radiomics-based machine learning (ML) model for locally advanced cancer (LAGC), specifically predict whether will achieve major pathological response (MPR) following neoadjuvant immunotherapy. With its predictive capabilities, this tool shows promise enhancing clinical decision-making processes the future. utilized multicenter cohort design, retrospectively gathering data computed tomography (CT) images from 268 diagnosed who underwent between January 2019 December 2023 two medical centers. Radiomic features were extracted CT images, multi-step feature selection procedure was applied identify top 20 representative features. Nine ML algorithms implemented build prediction models, optimal algorithm selected final model. The hyperparameters of chosen fine-tuned using Bayesian optimization grid search. performance evaluated several metrics, including area under curve (AUC), accuracy, Cohen's kappa coefficient. Three cohorts included study: development (DC, n = 86), internal validation (IVC, 59), external (EVC, 52). models developed DC cases. Among these, an optimized Bayesian-LightGBM model, demonstrated robust MPR LAGC across all cohorts. Specifically, within DC, LightGBM attained AUC 0.828, overall accuracy 0.791, coefficient 0.552, sensitivity 0.742, specificity 0.818, positive value (PPV) 0.586, negative (NPV) 0.867, Matthews correlation (MCC) 0.473, balanced 0.780. Comparable metrics validated both IVC EVC, values 0.777 0.714, accuracies 0.729 0.654, respectively. These results suggested good fitness generalization Shapley Additive Explanations (SHAP) analysis identified significant radiomic contributing model's capability. SHAP wavelet.LLH_gldm_SmallDependenceLowGrayLevelEmphasis, wavelet.HHL_glrlm_RunVariance, wavelet.LLH_glszm_LargeAreaHighGrayLevelEmphasis ranked among three, highlighting their contribution performance. In contrast existing that exclusively focus on chemotherapy, our integrates thereby offering more precise capabilities. efficacy predicting patients, providing foundation personalized treatment strategies.
Language: Английский
Citations
0
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2025, Volume and Issue: unknown, P. 189336 - 189336
Published: April 1, 2025
Language: Английский
Citations
0
Annals of Medicine, Journal Year: 2025, Volume and Issue: 57(1)
Published: May 7, 2025
The optimal time to chemotherapy (TTC) in locally advanced gastric cancer (LAGC) patients treated with neoadjuvant (NLAGC) remains unclear. Consecutive 524 NLAGC between Jan. 2010 and Dec. 2022 were identified. Patients categorized into three groups: TTC < 6w, 6w ≤ 8w, > 8w. Survival analysis was conducted using the Cox proportional hazards model assess impact of on cancer-specific mortality (GCSM) all-cause (ACM). Cumulative competing risk curves employed evaluate incidence events. Overall, 451 included.Cumulative showed that 3-year ACM GCSM significantly lower 8w group (ACM: 19.7% vs. 37.2% 39.7%, GCSM: 35.2% 38.8%) compared groups. Compared those or >8w had an increased (HR: 2.792 HR: 2.343, respectively) 3.102 2.719, after adjusting for confounders. Furthermore, later peak recurrence (Peak months: 9.7 4.3 3.1). A postoperative timing 6-8 weeks associated better survival delayed patients. These findings suggest week time-window should be a key timeframe personalized adjuvant decisions.
Language: Английский
Citations
0
Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16
Published: May 14, 2025
Gastric cancer (GC) is one of the primary contributors to cancer-related mortality on a global scale. It holds position within top five most prevalent malignancies both in terms occurrence and fatality rates. Immunotherapy, as breakthrough treatment, brings new hope for GC patients. Various biomarkers, such expression programmed death ligand-1 (PD-L1), microsatellite instability (MSI) status, tumor mutational burden (TMB), Epstein–Barr virus (EBV) infection, demonstrate potential predict effectiveness immunotherapy treating GC. Nevertheless, each biomarker has its own limitations, which leads significant portion patients continue be unresponsive immunotherapy. With understanding immune microenvironment (TIME), genome sequencing technology, recent advances molecular biology, markers, POLE/POLD1mutations, circulating DNA, intestinal flora, lymphocyte activation gene 3 (LAG-3), lipid metabolism have emerged. This review aims consolidate clinical evidence offer thorough comprehension existing emerging biomarkers. We discuss mechanisms, prospects application, limitations biomarker. anticipate that this will open avenues fresh perspectives investigation biomarkers promote precise choice treatment modalities gastric patients, thereby advancing precision immuno-oncology endeavors.
Language: Английский
Citations
0
Clinical Cancer Research, Journal Year: 2024, Volume and Issue: 31(1), P. 74 - 86
Published: Nov. 4, 2024
Neoadjuvant immunochemotherapy (NAIC) markedly induces pathologic regression in locally advanced gastric adenocarcinoma. However, specific biomarkers are still lacking to effectively identify the beneficiary patients for NAIC.
Language: Английский
Citations
1
Cancer Science, Journal Year: 2024, Volume and Issue: unknown
Published: Dec. 10, 2024
Abstract Immune checkpoint inhibitors combined with chemotherapy have shown promising efficacy in treating gastric or gastroesophageal junction (G/GEJ) adenocarcinoma the neoadjuvant setting. This phase II trial (NCT05715632) aimed to investigate and safety of perioperative camrelizumab plus XELOX patients locally advanced G/GEJ adenocarcinoma. Treatment‐naive cT3‐4aN1‐3 M0 resectable were recruited receive (200 mg, intravenously) on Day 1 (oxaliplatin at 130 mg/m 2 capecitabine 1000 Days 1–14) every 3 weeks for four cycles, followed by surgery adjuvant cycles. The primary endpoint was pathological complete response (pCR; ypT0N0) rate. From September 2020 January 2023, 46 enrolled, all completed therapy. Among them, 43 underwent D2 resection. In intention‐to‐treat population, pCR achieved nine (19.6%, 95% confidence interval [CI]: 9.9%–34.4%), major 25 (54.3%, CI: 39.2%–68.8%). objective rate 69.6%, which 12 a 20 partial response. 1‐year event‐free survival disease‐free rates both 93.1%. Treatment‐related adverse events (TRAEs) occurred 42 (91.3%) patients, grade TRAEs (19.6%) patients. No grades 4–5 observed. Perioperative showed an acceptable profile
Language: Английский
Citations
1
Heliyon, Journal Year: 2024, Volume and Issue: 10(20), P. e38710 - e38710
Published: Oct. 1, 2024
Language: Английский
Citations
0